NVP-1203-R1 + NVP-1203-R2

NVP-1203-R1 + NVP-1203-R2 is an experimental recombinant protein subunit vaccine candidate developed by Novartis for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine targets the RSV fusion (F) protein, a critical surface glycoprotein that mediates viral entry and syncytia formation. The R1 and R2 designations refer to specific formulations or manufacturing releases evaluated in early-phase clinical trials (such as NCT02296359) to assess safety, tolerability, and immunogenicity in healthy adults. Development of this specific asset under the Novartis pipeline was discontinued following the 2015 divestment of Novartis's non-influenza vaccine business to GSK, which subsequently prioritized its own RSV vaccine programs.

Other names

RSV-F vaccineNovartis RSV vaccine